Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of LABP
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Landos Biopharma, Inc. stock price down 0.80% on Tuesday
(Updated on Apr 30, 2024)

Buy or Hold candidate since Jan 02, 2024 Gain 416.20% PDF

The Landos Biopharma, Inc. stock price fell by -0.80% on the last day (Tuesday, 30th Apr 2024) from $22.48 to $22.30. During the last trading day the stock fluctuated 1.26% from a day low at $22.18 to a day high of $22.46. The price has risen in 8 of the last 10 days and is up by 3.62% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -2 thousand shares and in total, 2 thousand shares were bought and sold for approximately $37.26 thousand.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 16X during the next 3 months and, with a 90% probability hold a price between $292.33 and $413.84 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

LABP Signals & Forecast

The Landos Biopharma, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $22.27 and $17.93. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, April 25, 2024, and so far it has fallen -0.84%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Landos Biopharma, Inc. stock

Landos Biopharma, Inc. finds support from accumulated volume at $21.56 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0.280 between high and low, or 1.26%. For the last week the stock has had daily average volatility of 1.68%

Our recommended stop-loss: $21.45 (-3.81%) (This stock has low daily movements and this gives low risk. There is a sell signal from a pivot top found 3 days ago.)

Trading Expectations (LABP) For The Upcoming Trading Day Of Wednesday 1st

For the upcoming trading day on Wednesday, 1st we expect Landos Biopharma, Inc. to open at $22.31, and during the day (based on 14 day Average True Range), to move between $21.84 and $22.76, which gives a possible trading interval of +/-$0.459 (+/-2.06%) up or down from last closing price. If Landos Biopharma, Inc. takes out the full calculated possible swing range there will be an estimated 4.12% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $22.31 (0.04%) than the support at $21.56 (3.32%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Landos Biopharma, Inc. stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Landos Biopharma, Inc. stock to perform well in the short-term.

Current score: 2.828 Buy Candidate Unchanged

Predicted Opening Price for Landos Biopharma, Inc. of Wednesday, May 1, 2024

Fair opening price May 1, 2024 Current price
$22.31 ( 0.0598%) $22.30

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for LABP

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 22.59 1.32 %
R2 22.49 0.84 %
R1 22.42 0.539 %
Current price: 22.30
Support S1 22.21 -0.420 %
S2 22.14 -0.716 %
S3 22.03 -1.20 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 22.49 0.85 %
R2 22.48 0.81 %
R1 22.31 0.0448 %
Current price 22.30
Support S1 21.56 -3.32%
S2 21.50 -3.59%
S3 21.40 -4.04%

FAQ

What is the symbol for Landos Biopharma, Inc. Stock and on which exchange is it traded?
The symbol for Landos Biopharma, Inc. is LABP and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Landos Biopharma, Inc. Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Landos Biopharma, Inc. stock to perform well in the short-term.

How to buy Landos Biopharma, Inc. Stock?
Landos Biopharma, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Landos Biopharma, Inc. Stock.

What's the current price of Landos Biopharma, Inc. Stock?
As of the end of day on the Apr 30, 2024, the price of an Landos Biopharma, Inc. (LABP) share was $22.30.

What is the 52-week high and low for Landos Biopharma, Inc. Stock?
The 52-week high for Landos Biopharma, Inc. Stock is $22.84 and the 52-week low is $0.260.

What is the market capitalization of Landos Biopharma, Inc. Stock?
As of the Apr 30, 2024, the market capitalization of Landos Biopharma, Inc. is 70.12M.

When is the next earnings date for Landos Biopharma, Inc.?
The upcoming earnings date for Landos Biopharma, Inc. is May 10, 2024.
Click to get the best stock tips daily for free!

About Landos Biopharma, Inc.

Landos Biopharma. Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted ora... LABP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT